MedTrace Logo

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients

NCT04205552 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-05-09

No results posted yet for this study

Summary

The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Nivolumab, and Nivolumab plus Relatlimab in patients with early stage or locally advanced non-small cell lung cancer eligible for curative resection.

Conditions

  • NSCLC Stage II
  • NSCLC, Stage IIIA
  • NSCLC, Stage I

Interventions

DRUG

Nivolumab 10 MG/ML Intravenous Solution

Neoadjuvant 2 cycles, every two weeks (q2w) Nivolumab 240 mg i.v. over 30 min

DRUG

Relatlimab 10 MG/ML Intravenous Solution

Neoadjuvant 2 cycles, every two weeks (q2w) Relatlimab 80 mg i.v. over 30 min

Sponsors & Collaborators

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Martin Schuler, Prof. Dr. · University Hospital, Essen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-04
Primary Completion
2025-03-31
Completion
2025-06-30

Countries

  • Belgium
  • Germany
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04205552 on ClinicalTrials.gov